Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).

Standard

Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). / Ströbel, P; Murumägi, A; Klein, R; Luster, M; Lahti, M; Krohn, K; Schalke, B; Nix, W; Gold, R; Rieckmann, P; Toyka, K; Burek, C; Rosenwald, A; Müller-Hermelink, H K; Pujoll-Borrell, R; Meager, A; Willcox, N; Peterson, P; Marx, Andreas.

In: J PATHOL, Vol. 211, No. 5, 5, 2007, p. 563-571.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Ströbel, P, Murumägi, A, Klein, R, Luster, M, Lahti, M, Krohn, K, Schalke, B, Nix, W, Gold, R, Rieckmann, P, Toyka, K, Burek, C, Rosenwald, A, Müller-Hermelink, HK, Pujoll-Borrell, R, Meager, A, Willcox, N, Peterson, P & Marx, A 2007, 'Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).', J PATHOL, vol. 211, no. 5, 5, pp. 563-571. <http://www.ncbi.nlm.nih.gov/pubmed/17334980?dopt=Citation>

APA

Ströbel, P., Murumägi, A., Klein, R., Luster, M., Lahti, M., Krohn, K., Schalke, B., Nix, W., Gold, R., Rieckmann, P., Toyka, K., Burek, C., Rosenwald, A., Müller-Hermelink, H. K., Pujoll-Borrell, R., Meager, A., Willcox, N., Peterson, P., & Marx, A. (2007). Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J PATHOL, 211(5), 563-571. [5]. http://www.ncbi.nlm.nih.gov/pubmed/17334980?dopt=Citation

Vancouver

Bibtex

@article{061829ef3c1a4b2f892291f7501734a0,
title = "Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).",
abstract = "Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in 'central' tolerance in both humans and mice. However, while inactivating AIRE mutations result in the 'autoimmune polyendocrinopathy syndrome type 1' (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable tools to test conclusions drawn from mouse models. Here we show, in a large series, that approximately 95% of thymoma patients are 'chimeric'; expression of AIRE and major AIRE-related autoantigens (eg insulin) were undetectable in their tumours but maintained in their remnant thymic tissue and lymph nodes. Notably, despite the AIRE-deficient thymopoiesis in thymomas, disorders and autoantibodies typical of APS-1 were distinctly uncommon in these patients. The one striking similarity was in the recently observed neutralizing anti-type I interferon (IFN) antibodies, which are found at diagnosis in 100% of patients with APS-1 and in approximately 60% of patients with thymomas, as we show here. We conclude that APS-1 type autoantigens must be protected from autoimmunity by mechanisms that do not extend to the muscle autoantigens so frequently targeted in thymoma patients but so rarely recognized in APS-1. Thus our findings argue strongly for a tolerogenic function of AIRE beyond its role in negative T-cell selection in human thymopoiesis, and/or for specific autoimmunization against muscle in thymomas.",
author = "P Str{\"o}bel and A Murum{\"a}gi and R Klein and M Luster and M Lahti and K Krohn and B Schalke and W Nix and R Gold and P Rieckmann and K Toyka and C Burek and A Rosenwald and M{\"u}ller-Hermelink, {H K} and R Pujoll-Borrell and A Meager and N Willcox and P Peterson and Andreas Marx",
year = "2007",
language = "Deutsch",
volume = "211",
pages = "563--571",
journal = "J PATHOL",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).

AU - Ströbel, P

AU - Murumägi, A

AU - Klein, R

AU - Luster, M

AU - Lahti, M

AU - Krohn, K

AU - Schalke, B

AU - Nix, W

AU - Gold, R

AU - Rieckmann, P

AU - Toyka, K

AU - Burek, C

AU - Rosenwald, A

AU - Müller-Hermelink, H K

AU - Pujoll-Borrell, R

AU - Meager, A

AU - Willcox, N

AU - Peterson, P

AU - Marx, Andreas

PY - 2007

Y1 - 2007

N2 - Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in 'central' tolerance in both humans and mice. However, while inactivating AIRE mutations result in the 'autoimmune polyendocrinopathy syndrome type 1' (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable tools to test conclusions drawn from mouse models. Here we show, in a large series, that approximately 95% of thymoma patients are 'chimeric'; expression of AIRE and major AIRE-related autoantigens (eg insulin) were undetectable in their tumours but maintained in their remnant thymic tissue and lymph nodes. Notably, despite the AIRE-deficient thymopoiesis in thymomas, disorders and autoantibodies typical of APS-1 were distinctly uncommon in these patients. The one striking similarity was in the recently observed neutralizing anti-type I interferon (IFN) antibodies, which are found at diagnosis in 100% of patients with APS-1 and in approximately 60% of patients with thymomas, as we show here. We conclude that APS-1 type autoantigens must be protected from autoimmunity by mechanisms that do not extend to the muscle autoantigens so frequently targeted in thymoma patients but so rarely recognized in APS-1. Thus our findings argue strongly for a tolerogenic function of AIRE beyond its role in negative T-cell selection in human thymopoiesis, and/or for specific autoimmunization against muscle in thymomas.

AB - Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in 'central' tolerance in both humans and mice. However, while inactivating AIRE mutations result in the 'autoimmune polyendocrinopathy syndrome type 1' (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable tools to test conclusions drawn from mouse models. Here we show, in a large series, that approximately 95% of thymoma patients are 'chimeric'; expression of AIRE and major AIRE-related autoantigens (eg insulin) were undetectable in their tumours but maintained in their remnant thymic tissue and lymph nodes. Notably, despite the AIRE-deficient thymopoiesis in thymomas, disorders and autoantibodies typical of APS-1 were distinctly uncommon in these patients. The one striking similarity was in the recently observed neutralizing anti-type I interferon (IFN) antibodies, which are found at diagnosis in 100% of patients with APS-1 and in approximately 60% of patients with thymomas, as we show here. We conclude that APS-1 type autoantigens must be protected from autoimmunity by mechanisms that do not extend to the muscle autoantigens so frequently targeted in thymoma patients but so rarely recognized in APS-1. Thus our findings argue strongly for a tolerogenic function of AIRE beyond its role in negative T-cell selection in human thymopoiesis, and/or for specific autoimmunization against muscle in thymomas.

M3 - SCORING: Zeitschriftenaufsatz

VL - 211

SP - 563

EP - 571

JO - J PATHOL

JF - J PATHOL

SN - 0022-3417

IS - 5

M1 - 5

ER -